Patch AND QUIT Spółka z Ograniczoną Odpowiedzialnością w Likwidacji (KRS 0001178337, NIP 8133935343) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Patch AND QUIT Spółka z Ograniczoną Odpowiedzialnością w Likwidacji operates in: Manufacture of pharmaceutical preparations (PKD 21.20.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since June 12, 2025.
Entity dissolved
The data shown reflects the last known state before removal.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile (archived data) - Patch AND QUIT
Identity
- Name
- Patch AND QUIT Spółka z Ograniczoną Odpowiedzialnością w Likwidacji
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 12, 2025
- Registry status as of
- June 29, 2026
- Latest entry
- June 29, 2026
- Founding act
- 04.06.2025R.
Articles of association history (2)
- June 4, 2025: 04.06.2025R.
- March 25, 2026: 25.03.2026R., ZMIANA § 3
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Last known registered address
Archived data - last known state
- Address
- UL. WĄWOZOWA, 8, 97, 02-796, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-27792-39825-STRDB-22
Operational status - Patch AND QUIT
Status as of the last registry entry
Founded
June 12, 2025
1 year in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
21.20.Z
Manufacture of pharmaceutical preparations
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
N/A
Filed years
N/A
Registry entries
9
latest: June 29, 2026
Risk signals
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Patch AND QUIT.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) – the only Polish manufacturer of biosynthetic human insulin – closed 2025 with revenue of PLN 235.9m and EBITDA of PLN 53.82m (an 18.72% margin), but a net loss of around PLN 16.4m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6m), driven by international expansion (Malaysia at ~PLN 100m a year) and a contract to produce the insulin analogue glargine. Yifan Pharmaceutical controls 31.65% of the capital indirectly.
News
Celon Pharma 2025: record PLN 244m revenue, but the net loss deepens to PLN 79.4m – the 2026 outlook hinges on Salmex in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin near Łomianki) closed 2025 with consolidated revenue of PLN 244.34m (+17.9% YoY), EBITDA of PLN 21.42m (+42%) and a deeper net loss of PLN 79.36m (versus PLN 34.45m a year earlier). The wider loss reflects spending on the innovative GLP-1 segment. The generics segment grew 15.3% and accounts for 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of the capital and 68.2% of voting rights through Glatton sp. z o.o.
